Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Recruiting

Phase 1

LP-118Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Sponsor:

Newave Pharmaceutical Inc

Code:

NCT04771572

Conditions

Non Hodgkin Lymphoma

Richter Transformation

Multiple Myeloma

T-cell-prolymphocytic Leukemia

Acute Myeloid Leukemia

Eligibility Criteria

Sex: All

Age: 13+

Healthy Volunteers: Not accepted

Interventions

LP-118

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-14. This information was provided to ClinicalTrials.gov by Newave Pharmaceutical Inc on 2026-05-05.